When treating patients with mesothelioma or pleural disease, Penn Medicine pleural specialists offer more treatment options than most other health systems across the country and around the world.
Penn Medicine's Mesothelioma and Pleural Program and Penn's Abramson Cancer Center in Philadelphia, PA bring together internationally renowned experts in medical, surgical and radiation oncology and pulmonology who collaborate in the diagnosis, treatment and research of mesothelioma and pleural disease.
Mesothelioma is a rare type of cancer that affects the lining of the chest or abdominal cavities. It is most often attributed to exposure to airborne asbestos particles and occurs in both men and women. Asbestos fibers are naturally occurring fibrous minerals that were commonly used in construction and thermal insulation as a fire retardant until the 1970s. Asbestos is still used in products, but regulations in place since the 1980s limit its use.
Air is breathed in through the nasal passageways, travels through the trachea and bronchi to the lungs.
Penn's multidisciplinary approach to cancer diagnosis and treatment provides better outcomes and gives patients access to the most advanced treatment, surgical techniques and clinical trials.
An accurate diagnosis is the key to providing patients with the high level of care that they require for mesothelioma or pleural disease. At Penn, specialists who have extensive experience diagnosing and treating these complex conditions employ the latest tests and tools to provide patients with a timely, accurate diagnosis.
Currently, there are no recommendations for screening for mesothelioma or pleural disease, like there are for breast or colon cancer. However, people who have been exposed to asbestos, or who are at an increased risk for mesothelioma and pleural disease, should speak with their physician about screening tests that may detect early signs of cancer.
Physicians at Penn Medicine also recommend that people who have been exposed to asbestos know the signs and symptoms of mesothelioma.
Mesothelioma can be difficult to diagnose because its symptoms can be similar to those of other diseases. Pleural specialists at Penn Medicine have significant experience with this disease and employ the most advanced, minimally invasive techniques to obtain an accurate diagnosis.
Diagnostic tools used by Penn’s Mesothelioma and Pleural Program include:
Staging is a way of describing a cancer, such as where it is located, if or where it has spread, and if it is affecting the functions of other organs in the body. Doctors use diagnostic tests to determine the cancer's stage, so staging may not be complete until all the tests are finished. Knowing the stage helps the doctor to decide what kind of treatment is best and can help predict a patient's chance of recovery.
Once a diagnosis of mesothelioma is confirmed, staging of the disease is the next step in determining potential treatment options. Mesothelioma staging requires knowledge about where the tumor is located, how extensive it is in that location, whether the tumor metastasized to organs or adjacent tissues, and if it has spread to lymph nodes. Non-invasive staging is determined by the results of CT and/or MRI of the chest/abdomen/pelvis, PET scans and brain scans.
Invasive staging studies include various surgical procedures:
The International Mesothelioma Interest Group and Brigham & Women's Hospital have developed staging systems based upon a set of disease characteristics, which include:
Based on each of these three characteristics in combination, the stage of the mesothelioma is determined and, from this stage, a treatment plan is developed. A brief summary of each stage is described below:
Stage I: Mesothelioma affects the pleural space on only one side of the body but has not yet spread to other organs or the lymph nodes.
Stage II: Mesothelioma has spread more extensively within the pleural space or even into the lung itself and may also have extended into the diaphragm but has still not reached the lymph nodes or distant sites.
Stage III: Mesothelioma may have spread to the lymph nodes near the tumor, but would not have spread as far as the collarbone. It may also have spread into the chest wall, or even into the outer layer covering the heart, but has not yet spread to the other side of the chest or to distant sites.
Stage IV: Mesothelioma may have spread into the chest wall muscle, the ribs, the trachea, the esophagus, the spine, to the other side of the chest, or into the heart itself. Mesothelioma is also classified at Stage IV if it affects lymph nodes near the collarbone or has spread to distant sites.
Penn Medicine's pleural specialists develop personalized treatment plans for patients with mesothelioma and pleural disease, designed to give every patient the best possible outcome. Penn's treatment options for mesothelioma and pleural disease include:
Patients who come to Penn Medicine for their cancer care benefit from coordinated care across disciplines and modalities. The expertise of Penn's Abramson Cancer Center in cancer diagnosis, treatment planning and integrated medicine, helps patients who come to Penn Mesothelioma and Pleural Program receive nationally recognized care that leads to better outcomes and improved quality of life.
At Penn Medicine, significant research in the diagnosis and treatment of mesothelioma and pleural disease is giving patients with these conditions new hope for long-term survival.
To meet patients' varied physical, emotional and financial needs, Penn's robust network of navigation specialists includes social workers, stress management specialists, alternative medicine practitioners and clergy. Additionally, the support groups and survivorship programs at Penn provide patients and their families with a valuable network that serves to enhance and extend the quality of life following a cancer diagnosis.
By the age of seven, Tanya Zekovitch already understood what it was like to be a cancer patient after being treated for Ewing's Sarcoma, a rare form of bone cancer. So when she was diagnosed with Acute Myeloid Leukemia in the summer
Peter O'Dwyer, MD, professor of Hematology-Oncology and program director of Development Therapeutics in the Abramson Cancer Center, was interviewed on NBC10's 10! Show about Penn's work as part of the Stand Up to Cancer Dream Team... Read more